AN2 Therapeutics Q2 net loss widens on higher R&D costs

AN2 Therapeutics

11/08/2026 21:09

Overview
U.S. biopharma firm's Q2 net loss widened yr/yr on higher R&D expenses
Company ended Q2 with $79.9 mln in cash, expects runway into 2029
AN2 advancing three Phase 2 studies and expanding pipeline in 2026

Outlook
Company expects to initiate Phase 2 trial for chronic Chagas disease in late 2026
AN2 to begin enrollment in global Phase 2 polycythemia vera trial in Q4 2026
Company expects to advance a second boron-based development candidate by end of 2026

Result Drivers
R&D EXPENSES - Higher Q2 research and development costs driven by expanded clinical trial activities, chemistry manufacturing and controls, consulting, preclinical and research studies, and clinical trial expenses
PIPELINE EXPANSION - Increased operational costs as company advanced three Phase 2 studies and declared new development candidates for solid tumors

Company press release: ID:nBw5cncZYa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.18
 
Q2 Net Loss
 
$8.19 mln
 
Q2 Income From Operations
 
-$8.90 mln
 
Q2 Operating Expenses
 
$8.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for AN2 Therapeutics Inc is $9.00, about 52.3% above its August 10 closing price of $5.91

Reuters Recommended Reads
Aug 10 - Palisade Bio Q2 net loss widens on higher R&D costs
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)